加码研发亏损收窄,君实生物核心产品三季度营收增长80%

观察者网
01 Nov 2024

(文/王力 编辑/徐喆)10月29日晚间,君实生物(1877.HK,688180.SH)公布了其2024年前三季度报告。财报显示,公司在报告期内实现了12.71亿元人民币的营业总收入,同比增长28.87%。尽管营收有所增长,但归属于上市公司股东的净利润仍为负值,亏损9.27亿元人民币,同比增长34.12%。公司指出,营业收入的增长主要得益于其商业化药品销售收入的提升,尤其是核心产品特瑞普利单抗(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10